$118 Million Offering Should Position Sarepta Strongly For Partnering Talks
This article was originally published in The Pink Sheet Daily
Executive Summary
As the Duchenne muscular dystrophy-focused biotech raises significant cash from institutional investors, CEO clarifies that Sarepta is intent on finding the right partner, structure and economics for an ex-North American opportunity.